Skip to main content

EU Training Network on Novel Targets and Methods in Atrial Fibrillation

Objective

The AFib-TrainNet consortium will enable promising young scientists to become excellent research leaders of the future, capable of fighting the challenges that Atrial Fibrillation (AF) presents to the European population. AF is the most common sustained cardiac arrhythmia, occurring in between 1-2% of the general population. More than 6 million Europeans suffer from this arrhythmia and its prevalence is expected to increase by more than two-fold during the next 40 years due to increased life expectancy. Thus, AF is said to assume epidemic proportions. Current options for pharmacological therapy are limited by both low efficacy and side effects, including life‐threatening ventricular arrhythmias and severe extra-cardiac toxicities.
A very limited number of novel AF drug therapies have been introduced in the last 20 years. This imbalance reflects a gap in understanding in both how AF develops and how it can be treated, which thereby limits the development of new medicines. Our ambition with the AFib-TrainNet is to fill this gap by producing new knowledge, leading to critical insight into origins and mechanisms of sustenance of atrial fibrillation. We will accomplish this by developing novel experimental and computational models recapitulating human AF, and employing these models on two very promising atrial biological targets. Experimental models will be instrumental in improving the understanding AF’s underlying mechanisms, and will, along with clinical data, inform state-of-the-art computational models of human atrial electrophysiology. These new tools will permit fresh insight into the molecular, cellular and electrical mechanisms involved in the progression of healthy atria into an AF state. Our endeavor will deliver results which can be leveraged by the pharmaceutical industry to target AF drug development, and the work accomplished in AFib-TrainNet will thus constitute a beacon in the search for new AF medicine.

Coordinator

KOBENHAVNS UNIVERSITET
Net EU contribution
€ 870 245,64
Address
Norregade 10
1165 Kobenhavn
Denmark

See on map

Region
Danmark Hovedstaden Byen København
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (6)

SIMULA RESEARCH LABORATORY AS
Norway
Net EU contribution
€ 572 550,48
Address
Kristian August Gate 23
0164 Oslo

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Research Organisations
Non-EU contribution
€ 0,00
UNIVERSITY OF GLASGOW
United Kingdom
Net EU contribution
€ 546 575,76
Address
University Avenue
G12 8QQ Glasgow

See on map

Region
West Central Scotland Glasgow City
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITEIT MAASTRICHT
Netherlands
Net EU contribution
€ 510 748,56
Address
Minderbroedersberg 4
6200 MD Maastricht

See on map

Region
Limburg (NL) Zuid-Limburg
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany
Net EU contribution
€ 747 649,44
Address
Martinistrasse 52
20251 Hamburg

See on map

Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
ACESION PHARMA APS
Denmark
Net EU contribution
€ 580 163,76
Address
Ole Maaloes Vej 3
2200 Kobenhavn

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
CLYDE BIOSCIENCES LIMITED
United Kingdom
Net EU contribution
€ 273 287,88
Address
Biocity Scotland Bo'ness Road
ML1 5UH Motherwell Lanarkshire

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West Central Scotland North Lanarkshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00

Partners (4)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

XENTION LTD
United Kingdom
Net EU contribution
€ 0,00
Address
Iconix Park, London Road, Pampisford
CB22 3EG Cambridge

See on map

Region
East of England East Anglia Cambridgeshire CC
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

BEN-GURION UNIVERSITY OF THE NEGEV
Israel
Net EU contribution
€ 0,00
Non-EU contribution
€ 0,00
Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN
Austria
Net EU contribution
€ 0,00
Non-EU contribution
€ 0,00
Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

FONDAZIONE CARDIOCENTRO TICINO
Switzerland
Net EU contribution
€ 0,00
Address
Via Tesserete 48
6900 Lugano

See on map

Region
Schweiz/Suisse/Svizzera Ticino Ticino
Activity type
Research Organisations
Non-EU contribution
€ 0,00